Leah Lawrence

Leah Lawrence is a freelance health writer and editor based in Delaware. She has contributed to trade, consumer, and medical association publications and websites focused on hematology/oncology, cardiology, primary care, endocrinology, and general health.

All articles by Leah Lawrence

Bisphosphonates may reduce risk of certain breast, colon, and lung cancers

Thirty Percent of Patients With NSCLC Who Had Actionable Variants Were Not Prescribed Targeted Therapies: Study

By

Leah Lawrence

May 30, 2020

The VA NPOP is a program established to provide access to next-generation sequencing for veterans with advanced solid tumors.

Although the rate of cancer misdiagnosis is quite high across malpractice claims, this number does not necessarily correlate with what occurs in clinical practice, an expert warned.

Anti-TIGIT Drug Improved Overall Response Rate, Progression-Free Survival in PD-L1-Selected NSCLC

By

Leah Lawrence

May 30, 2020

Updated results confirmed benefit seen in primary analysis.

A Majority of Anticancer Drug Approvals Are Based on Trials With Core Limitations, Say Researchers

By

Leah Lawrence

May 30, 2020

Core limitations were defined as lack of randomization, lack of overall survival data, inappropriate use of crossover, and use of suboptimal control arms.

Second-line mFOLFOX3 has modest effect in unresectable and/or metastatic biliary tract cancer.

Single, Priming Dose of Tremelimumab Plus Durvalumab Active in Second-Line Hepatocellular Carcinoma

By

Leah Lawrence

May 30, 2020

Trememlimumab thought to induce immune response.

Increased travel burden is associated with a decreased likelihood of receiving adjuvant chemotherapy

Patient Relapse Time After Auto-HCT in Chemosensitive DLBCL Does Not Appear to Influence PFS

By

Leah Lawrence

May 30, 2020

The data reinforce the need for direct comparison of CAR-T and autologous transplantation.

Over half of evaluable patients who received an infusion of tisagenlecleucel achieved response.

Dual-Targeting CAR-T Appears Active in R/R DLBCL

By

Leah Lawrence

May 30, 2020

The Alexander study was designed to test if dual-targeting of CD19 and CD22 would reduce the likelihood of antigen escape.

Emerging evidence suggests that a better understanding of T-cell behavior may help immune checkpoint inhibitors become more personalized.

Researchers Work to Establish a National Biorepository to Study irAEs

By

Leah Lawrence

May 29, 2020

More than 350 sites have been approved for participation in the biobanking effort.

Micrograph of non-Hodgkin lymphoma

Allogeneic CAR-T Therapies Appear Safe in LBCL/FL

By

Leah Lawrence

May 29, 2020

The “universal” products have the potential to address the challenges of autologous CAR-T.

breast cancer surgery

First-Line Pembrolizumab Plus Chemotherapy Improved PFS in PD-L1–Positive mTNBC

By

Leah Lawrence

May 29, 2020

There was a trend toward improved efficacy with PD-L1 enrichment.

DLBCL is a rare, B-cell non-Hodgkin’s lymphoma that affects older adults.

Real-World Data Back Efficacy of Axi-Cel in R/R DLBCL

By

Leah Lawrence

May 26, 2020

Even among those with more comorbidities, safety, efficacy of treatment remained.

Next post in Lymphoma

A doctor and patient discuss medical files.

Nivolumab Plus AVD Found Highly Effective in Early-Stage Unfavorable cHL